Literature DB >> 22888212

A retrospective cohort study of clinical outcomes for intravitreal crystalline retained lens fragments after age-related cataract surgery: a comparison of same-day versus delayed vitrectomy.

Elizabeth A Vanner1, Michael W Stewart, Thomas J Liesegang, Rick E Bendel, James P Bolling, Saiyid A Hasan.   

Abstract

BACKGROUND: This analysis compared outcomes for same-day (under a no-move, no-wait policy) versus delayed vitrectomy for intravitreal crystalline retained lens fragments after surgery for age-related cataract.
METHODS: This was a retrospective, nonrandomized treatment comparison cohort study with a consecutive series of 35 eyes (23 same-day, 12 delayed) receiving both cataract surgery and vitrectomy at the Mayo Clinic Florida between 1999 and 2010. Outcome measures included visual acuity (VA), glaucoma progression, visual utility, and complications. Several techniques (bootstrapping, robust confidence intervals, jackknifing, and a homogeneous sample) were used to reduce selection bias and increase confidence in our small sample's results.
RESULTS: No significant baseline treatment group differences. Mean previtrectomy delay (12 eyes) was 40.9 days (median 29.5, range 1-166). Mean postvitrectomy follow-up (35 eyes) was 47.5 months (median 40.5, range 3.1-123.5). Same-day patients had significantly better final VA (adjusted for age [t = -2.14, P = 0.040] and precataract surgery VA [t = -2.98, P = 0.006]); a higher rate of good final VA (≥20/40), 78.3% (18/23) versus 58.3% (7/12); a lower rate of bad final VA (≤20/200), 4.3% (1/23) versus 25.0% (3/12); and fewer final retinal conditions, 4.3% (1/23) versus 50.0% (6/12). Same-day patients also had marginally significant better mean final VA in the operated eye (20/40 versus 20/90, Z = 1.51, P = 0.130) despite poorer initial VA (20/98 versus 20/75) and higher age (3+ years), better final visual utility, and longer survival times for better VA. Among patients with preexisting glaucoma, same-day patients experienced significantly less differential (operated versus nonoperated eye) glaucoma progression.
CONCLUSION: Results favored same-day patients, who experienced better final VA and visual utility, less differential glaucoma progression, and fewer complications. Results need confirmation with larger samples.

Entities:  

Keywords:  evaluation studies; glaucoma; intraoperative complications; retained lens fragments; small nonrandomized sample analysis; statistics as topic; visual acuity; visual utility

Year:  2012        PMID: 22888212      PMCID: PMC3413336          DOI: 10.2147/OPTH.S27564

Source DB:  PubMed          Journal:  Clin Ophthalmol        ISSN: 1177-5467


Introduction

Phacoemulsification cataract surgery occasionally results in fragments or the entire crystalline lens dislocating into the vitreous. There is evidence that the clinical course for patients with retained lens fragments (RLF) begins the instant the fragments enter the vitreous and is affected by the cataract surgeon’s decisions and actions.1 Lack of immediate availability of an experienced vitreoretinal surgeon and the necessary equipment usually precludes a same-day vitrectomy, which many suggest might be the optimal time for RLF removal.2–6 Studies comparing same-day and delayed vitrectomy show mixed results. Several authors reported better visual acuity (VA)7–9 and lower rates of complications – retinal detachment (RD),7–10 corneal edema,10,11 glaucoma/elevated intraocular pressure (IOP),7–12 cystoid macular edema (CME),7,8,10 and intraocular inflammation/infection7,10,11 – among same-day patients. Lower rates of elevated IOP and/or CME may be related to less intraocular inflammation/infection.8,10 Others reported no significant differences in VA,13 RD,12 and IOP13 between same-day and delayed vitrectomy patients. This study compared outcomes of patients with RLF who received a same-day vitrectomy, under the Mayo Clinic Florida (MCF) “no move, no wait” policy, versus a delayed vitrectomy any day after cataract surgery. The MCF policy is that a same-day vitrectomy can be performed only if a vitreoretinal surgeon begins the procedure within 15 minutes of cataract surgery and the patient is not moved from the original operating room. Outcomes included VA, visual utility, new glaucoma cases, differential progression of preexisting glaucoma, and ocular complications. This study received institutional review board approval and an informed consent waiver from the MCF Institutional Review Board.

Methods

Patients, study design, and setting

This was a retrospective cohort study with a consecutive series of 34 patients (35 eyes) who had received both cataract surgery and vitrectomy at MCF (1999–2010). Inclusion criteria were scheduled phacoemulsification cataract surgery for an age-related cataract and intravitreal crystalline RLF managed surgically with a standard three-port pars plana vitrectomy. Twelve eyes (exposed to RLF for 1+ days) received a delayed vitrectomy (1999–2004) with mean delay of 40.9 days (median 29.5, range 1–166). Indications for vitrectomy in this delayed group included elevated IOP, excessive inflammation, CME, and/or decreased VA. Same-day vitrectomy (1999–2010) was successfully performed on 22 eyes and attempted on the remaining eye, but not completed due to an equipment problem. This patient’s data were analyzed in the same-day group, according to intention-to-treat,14 yielding an unexposed group with 23 eyes. All patients returned for follow-up visits (mean postvitrectomy follow up 47.5 months [median 40.5, range 3.1–123.5]) as per the standard of care, and data was abstracted from patients’ medical records.

Variables

All variables pertain to the operated eye unless otherwise noted. Snellen VA, measured during all visits, was converted to logarithm of the minimum angle of resolution (logMAR) for statistical analysis.15 Total elapsed time was from cataract surgery to final visit. The following were considered final retinal conditions: CME, RD, background diabetic retinopathy with focal laser photocoagulation, macular scar, and/or drusen; and we included the following as final corneal conditions: superficial scar, mild edema, and/or mild haze. We defined good VA as ≥20/40, bad VA as ≤20/200, and ocular inflammation as the presence of cells in the anterior chamber. New glaucoma cases included patients requiring long-term pressure-lowering drops (in the operated eye) after vitrectomy who did not require this before cataract surgery. Glaucoma progression was defined as the exacerbation of visual field abnormalities, calculated by subtracting precataract surgery mean deviation (MD) from final MD and precataract surgery pattern-specific deviation (PSD) from final PSD. Differential glaucoma progression was calculated (separately for MD and PSD) by subtracting glaucoma progression in the nonoperated (fellow) eye from glaucoma progression in the operated eye. Two scales were used for final visual utility: visual utility – better eye (based mainly on VA in the better eye)16 and visual utility – both eyes (adapted to use only VA data but from both eyes17 because RLF typically occur only in a single eye, often the one with worse VA). Because it is patient-specific (not eye-specific), the visual utility analyses contained only 22 same-day patients because one patient received a same-day vitrectomy in both eyes.

Data analyses

All analyses compared results for patients’ operated eyes by treatment group (same-day versus delayed) and were preformed using Stata/IC version 11.1 (StataCorp, College Station, TX, USA). When doing the analyses, exact tests (which do not rely on large-sample assumptions of asymptotic normality) were used whenever possible.18 In addition, model adjustment for potential confounding variables was limited because, in a small dataset, including too many variables in a model might result in overfitting.19 However, it was important to adjust these analyses for potential confounding variables to reduce the effects of selection bias, which is inherent when comparing nonrandomized samples.14,20 Potential confounding variables included patient age (at final visit), VA precataract surgery (the best proxy available for ocular health and vision before the RLF), and total elapsed time. See the appendix, which describes additional steps taken to reduce effects of selection bias and increase confidence in our small sample results. Continuous variables were assessed for normal distributions. Three types of models were built: analysis of covariance (ANCOVA) for final VA and final visual utility – better eye, ordinal logistic regression for final visual utility – both eyes, and exact Cox proportional-hazards regression for time from vitrectomy until VA decreased to and remained <20/40 and ≤20/200. An independent-samples t-test compared differential MD glaucoma progression, a Mann–Whitney test compared differential PSD glaucoma progression, and Fisher’s exact tests compared complication rates. Results were considered statistically significant with P-values ≤ 0.05.21,22 When appropriate, marginally significant differences (P ≤ 0.15) were noted because small samples are often underpowered to detect significant differences, even when treatment effects are real.14 Noting marginally significant results is as appropriate as a multiplicity of post hoc power analyses, and probably more informative, since it is specifically the marginally significant results which should be included in the hypotheses of larger studies to verify the small sample’s results. Discussing marginally significant results attempts to reduce the effect of type II errors (the failure of a statistical test to detect actual treatment group differences, when they exist), which are a problem associated with small-sample studies.14

Results

During the study period (1999–2010), 7565 patients had scheduled age-related cataract surgery at MCF, so these 35 cases indicate an RLF incidence rate of 0.46%. All 35 RLF cases were included in this study. Table 1 contains descriptive statistics and treatment group comparisons. There were no significant (or marginally significant) baseline group differences in any precataract surgery variable. There was a significant difference in the volume of RLF (same-day patients having larger amounts, P < 0.001) and a marginally significant difference in intraocular lens (IOL) type (more same-day patients had anterior-chamber IOLs, P = 0.084). For postvitrectomy variables, there were significant differences in both MD and PSD differential glaucoma progression (discussed below) and final retinal conditions (same-day = 4.3%, delayed = 50.0%; P = 0.003). There were also marginally significant differences in unadjusted final VA in the operated eye (same-day = 0.30, delayed = 0.65; Z = 1.51, P = 0.130), age at final visit (same-day = 84.43, delayed = 81.37; Z = −1.53, P = 0.126), bad final VA (same-day = 4.3% [1/23], delayed = 25.0% [3/12]; P = 0.106), and final visual utility – both eyes (same-day = 0.94, delayed = 0.91; Z = 1.54, P = 0.124). For all postvitrectomy clinical variables with significant or marginally significant differences, same-day patients had better results. Figure 1 compares precataract surgery and final VA (operated eye) and differential glaucoma progression (operated versus nonoperated eye) by treatment group.
Table 1

Patient characteristics and univariate tests of between-group differences

Means (M) and standard deviations (SD)Delayed (N = 12)Same-day (N = 23)


MSDMSDTestStatisticP-value
Age at Final Visit81.379.2184.438.41MW−1.530.126
logMAR VA OP pre-CS0.570.400.690.56MW−0.330.739
logMAR VA non-OP pre-CS0.260.190.300.24MW−0.210.832
FU post-vitrectomy (months)54.8237.7443.7033.26IS-t0.900.376
Total elapsed time (months)56.1838.3243.7033.26IS-t1.000.324
logMAR VA OP final0.650.740.300.47MW1.510.130
logMAR VA non-OP final0.210.180.280.33MW−0.040.972
Visual Utility-better eyea0.850.070.890.08IS-t−1.280.210
Visual Utility-both eyesa0.910.070.940.05MW−1.540.124
Diff MD glaucoma progression−5.622.960.173.41IS-t−2.880.016*
Diff PSD glaucoma progression2.002.76−1.201.11MW2.550.011*

Counts (n) and proportionsnPropnPropTestP-value

# right eye650.0%1356.5%Fischer exact0.736
# w/pseudo. pre-CS325.0%730.4%Fischer exact1.000
# w/polar cataract pre-CS18.3%00.0%Fischer exact0.343
# w/cortical lens pre-CS18.3%417.4%Fischer exact0.640
# w/glaucoma pre-CS433.3%1147.8%Fischer exact0.489
Cataract nuclear sclerosis (NS)
 NS = 4+00.0%313.0%Kendall’s tau0.813
 NS = 3+650.0%939.1%
 NS = 2+541.7%834.8%
 NS = 1+00.0%28.7%
 None18.3%14.3%
Posterior subcapsular cataract (PSC)
 PSC = 3+18.3%28.7%Kendall’s tau0.531
 PSC = 2+216.7%14.4%
 PSC = 1+00.0%28.7%
 None975.0%1878.3%
Intraocular lens type
 posterior chamber433.3%14.6%Fischer exact0.084
 anterior chamber433.3%1359.1%
 posterior sulcus433.3%836.4%
Volume of retained lens fragments
 Large111.1%19100.0%Kendall’s tau0.000***
 Moderate555.6%00.0%
 Small333.3%00.0%
 missing data34
# new glaucoma cases112.5%215.4%Fischer exact1.000
# w/final retinal condition650.0%14.3%Fischer exact0.003**
# w/retinal detachment216.7%14.3%Fischer exact0.266
# w/cystoid macular edema325.0%313.0%Fischer exact0.391
# w/final anterior chamber cells00.0%28.7%Fischer exact0.536
# w/final corneal condition216.7%14.3%Fischer exact0.266
# w/VA Snellen final < 20/40541.7%521.7%Fischer exact0.258
# w/VA Snellen final ≤ 20/200325.0%14.3%Fischer exact0.106

Notes:

P ≤ 0.05,

P ≤ 0.01,

P ≤ 0.001,

P ≤ 0.15. All data are for the operated eye unless noted.

Visual utility analyses included 22 same-day patients. Visual utility-better eye: 0.92 = 20/20 with < 20/40 in the other eye, 0.87 = 20/25, 0.84 = 20/30.16 Visual utility-both eyes: 0.96 = better eye 20/20—20/40 and worse eye >20/200, 0.88 = better eye 20/50—20/80 and worse eye >20/200.17

Abbreviations: Diff, Differential; FU, follow up time in months; IS-t, independent-samples t-test; MD, mean deviation; MW, Mann-Whitney rank-sum test; N, n, number of eyes; non-OP, non-operated eye; OP, operated eye; pre-CS, before cataract surgery; prop, proportion; PSD, pattern specific deviation; pseudo, pseudoexfoliation; VA, visual acuity; w/, with.

Figure 1

Box-and-whisker plot comparisons of precataract surgery (Pre-CS) logMAR visual acuity (VA) and final logMAR VA in the operated eye and differential glaucoma progression (exacerbation) (mean deviation [MD] and pattern-specific deviation [PSD]) by treatment group.

Table 2 displays descriptive statistics and normal distribution test results. For three dependent variables, final logMAR VA in the operated eye, visual utility – both eyes, and differential PSD glaucoma progression, a normal distribution could not be assumed. Analogous ANCOVA models, built with Snellen (normally distributed) and logMAR final VA, produced similar results. We report only the logMAR final VA models’ results, because it is a continuous variable,15 as required by ANCOVA. Attempts to transform the other two variables to normal distributions were unsuccessful.
Table 2

Descriptive statistics and normal distribution tests

Variable and its functionDelayed PPV (n = 12)Same-day PPV (n = 23)Skew/kurtosisb testShapiro–Wilkb test




MinMdMaxMinMdMaxadj χ2P-valueZP-value
Independent or confounding variables
 Age at final visit58.1381.9997.0362.7985.6599.458.630.013*2.200.014*
 VA logMAR OP pre-CS0.1760.4381.6020.1760.4772.20410.880.004**3.920.000***
 VA Snellen OP pre-CS20/80020/5520/3020/307720/6020/304.070.130−1.640.950
 VA logMAR non-OP pre-CS0.0000.1760.5440.0000.3011.00012.440.002**2.890.002**
 VA Snellen non-OP pre-CS20/7020/3020/2020/20020/4020/200.950.623−1.550.939
 FU post-PPV (months)5.9353.28113.373.0736.57123.502.830.2431.860.031*
 Total elapsed time (months)6.3356.57115.303.0736.57123.502.850.2401.890.030*
 VA logMAR non-OP final0.0000.0180.5440.0000.0971.30118.350.000***4.190.000***
 VA Snellen non-OP final20/7020/3020/2020/40020/2520/202.770.2500.320.374
Dependent variables
 VA logMAR OP final0.0970.3012.2040.0000.1762.20418.230.000***5.050.000***
 VA Snellen OP final20/320020/4020/2520/320020/3020/203.240.198−0.390.651
 Visual utility − better eyea0.740.840.970.770.871.004.150.1261.000.160
 Visual utility − both eyesa0.8050.960.960.830.960.967.270.026*3.040.001**
 Diff MD glaucoma prog−8.12−6.37−1.63−3.35−1.155.720.210.899−0.630.737
 Diff PSD glaucoma prog0.110.8956.11−2.76−0.850.3110.380.006**2.100.018*

Notes:

P ≤ 0.05;

P ≤ 0.01;

P ≤ 0.001;

P ≤ 0.15.

Visual utility analyses included 22 same-day patients. Visual utility – better eye: 1.00 = 20/20 bilaterally, permanently; 0.97 = 20/20 with 20/20 to 20/25 in the other eye, 0.92 = 20/20 with ≤20/40 in the other eye, 0.87 = 20/25, 0.84 = 20/30, 0.80 = 20/40, 0.77 = 20/50, 0.74 = 20/70.16 Visual utility – both eyes: 0.96 = better eye 20/20 to 20/40 and worse eye > 20/200, 0.88 = better eye 20/50 to 20/80 and worse eye > 20/200, 0.83 = better eye 20/20 to 20/40 and worse eye < 20/200, 0.88 = better eye 20/50 to 20/80 and worse eye < 20/200;17

the null hypothesis for the Skew/kurtosis test and the Shapiro–Wilk test is that the data come from a normal distribution.

Abbreviations: adj χ2, adjusted chi-square statistic; Diff, differential; FU, follow-up time in months; Max, maximum; Md, median; Min, minimum; n, number of eyes; non-OP, nonoperated eye; OP, operated eye; post-PPV, after pars plana vitrectomy; PPV, pars plana vitrectomy; pre-CS, before cataract surgery; prog, progression; VA, visual acuity; Z, Z statistic.

The models’ results are summarized in Table 3. ANCOVA (Table 4) indicated that same-day patients had significantly better adjusted final VA (models 1A and 1B) (age-adjusted difference = −0.42, 95% confidence interval [CI] = −0.83, −0.02, t = −2.14, P = 0.040 and precataract surgery VA-adjusted difference = −0.45, 95% CI = −0.75, −0.14, t = −2.98, P = 0.006) and marginally significant higher adjusted visual utility – better eye (models 2A and 2B), approximately the difference between 20/25 and 20/30 (age-adjusted difference = 0.04, 95% CI = −0.01, 0.10, t = 1.62, P = 0.116 and precataract surgery VA-adjusted difference = 0.04, 95% CI = −0.01, 0.09, t = 1.48, P = 0.149). Table 3 shows the results of using these ANCOVA models to estimate the patients’ mean final VA and visual utility – better eye if the patients had been in the other treatment group.
Table 3

Summary comparison of outcomes and actual vs estimated (based on statistical models) if patients had been in the other treatment group

Variable and modelTreatment groupnActual treatment group meansEstimated means if patients had been in the other treatment group


Pre-CSFinalUnadjustedAdjusted for ageAdjusted for pre-CS VA
Final VA in the operated eye (Table 4, model 1A and B)Same-day PPV eyes2320/9820/4020/9020/10620/112
Delayed PPV eyes1220/7520/9020/4020/3420/32
Visual utility – better eyea (Table 4, model 2A and B)Same-day patients22N/A0.890.850.890.89
Delayed patients12N/A0.850.890.840.85
Mean deviation (Table 5, model 6)Same-day PPV eyes8−11.07−10.32−17.33N/AN/A
Delayed PPV eyes4−5.53−8.33−2.53N/AN/A
Pattern-specific deviation (Table 5, model 7)Same-day PPV eyes86.585.959.65N/AN/A
Delayed PPV eyes43.935.912.70N/AN/A

Notes:

Visual utility analysis included 22 same-day patients. Visual utility – better eye: 0.92 = 20/20 with ≤20/40 in the other eye, 0.87 = 20/25, 0.84 = 20/30.16

Abbreviations: age, age at final visit; n, number of eyes; N/A, not applicable to this analysis because the adjustments based on these variables were not significant; PPV, pars plana vitrectomy; pre-CS, before cataract surgery; VA, visual acuity.

Table 4

Analysis of covariance (ANCOVA) and ordinal logistic regression models comparing final visual acuity in the operated eye and final visual utility (two scales)

Model: dependent variabledfSSMSFBtP-valueModelB: 95% CIBootstrapped CIB: 95% BC CIRobust CIB: 95% CIJackknifeΔ signif

ANCOVASource
1A: VA finalModel22.351.173.930.030*# BSR = 1000D (1, 9, 12)
Model propertiesGroupa11.371.374.57−0.42−2.140.040*(−0.83, −0.02)(−0.84, −0.03)*(−0.87, 0.03)
R-sq = 19.7%Age11.381.384.610.022.150.040*(0.00, 0.05)(0.01, 0.04)**(0.01, 0.04)**
Adj R-sq = 14.7%Total3411.910.35
1B: VA finalModel26.343.1718.220.000***# BSR = 1000None
Model propertiesGroupa11.541.548.86−0.45−2.980.006**(−0.75, −0.14)(−0.83, −0.16)**(−0.80, −0.92)*
R-sq = 53.2%VApreCS15.375.3730.870.795.560.000***(0.50, 1.08)(0.41, 1.14)***(0.41, 1.17)***
Adj R-sq = 50.3%Total3411.910.35
2A: Visual utility 1Model20.030.012.670.085# BSR = 1000D (1 and 2)
Model propertiesGroupa10.010.012.620.041.620.116(−0.01, 0.10)(−0.01, 0.09)(−0.01, 0.09)SD (16)
R-sq = 14.9%Age10.020.023.560.00−1.890.069(−0.01, 0.00)(−0.01, 0.00)(−0.01, 0.00)
Adj R-sq = 9.2%Total330.190.01
2B: Visual utility 1Model20.030.012.760.079# BSR = 1000D (1, 2, 4, 8–11)
Model propertiesGroupa10.010.012.190.041.480.149(−0.01, 0.09)(−0.01, 0.08)(−0.01, 0.09)
R-sq = 15.1%VApreCS10.020.023.75−0.05−1.940.062(−0.10, 0.00)(−0.11, −0.00)*(−0.10, 0.00)SD (6, 8, 12–16, 19 and 23)
Adj R-sq = 9.7%Total330.190.01
Ordinal logistic regressiondfLLχ2ORcZP-valueOR: 95% CIOR: 95% BC CIOR: 95% CIΔ signif

3A: Visual utility 2Model2−23.28.210.017*# BSR = 1116D (9)
Model propertyGroupa7.382.070.038*(1.12, 48.78)(1.14, 85.50)*(1.02, 53.16)*
P R-sq = 15.0%Age0.87−2.040.041*(0.75, 0.99)(0.76, 0.96)*(0.79, 0.95)**
3B: Visual utility 2Model2−21.910.840.004**# BSR = 1147None
Model propertyGroupa7.262.020.043*(1.06, 49.66)(1.14, 123.9)*(0.94, 55.98)
P R-sq = 19.9%VApreCS0.09−2.630.008**(0.02, 0.54)(0.01, 0.41)*(0.02, 0.40)***

Notes:

P ≤ 0.05;

P ≤ 0.01;

P ≤ 0.001;

P ≤ 0.15.

For the group variable, the reference category is delayed vitrectomy.

Abbreviations: age, age at final visit; Adj R-sq, adjusted R-squared; B, model coefficient and the adjusted mean difference between the treatment groups; BC, bias-corrected; BSR, bootstrap repetitions; CI, confidence interval; D ( ), delayed vitrectomy patients; df, degrees of freedom; F, F statistic; LL, log likelihood; MS, mean square; OR, odds ratio (OR greater than 1 indicates higher odds of better visual utility for patients with same-day vitrectomy); P R-sq, pseudo R-squared; R-sq, R-squared; SD ( ), same-day vitrectomy patients; SS, partial sum of squares; t, t statistic; VA final, logMAR VA in the operated eye at the final visit; VApreCS, logMAR VA in the operated eye before cataract surgery; VA, visual acuity; visual utility 1, visual utility − better eye; visual utility 2, visual utility − both eyes; Z, Z statistic; χ2, chi-square statistic; Δ signif, removal of these patients’ data caused a change in the model’s significance

Ordinal logistic regression (Table 4, models 3A and 3B) indicated that same-day patients had significantly higher odds of better adjusted visual utility – both eyes (age-adjusted odds ratio = 7.38, 95% CI = 1.12, 48.78, Z = 2.07, P = 0.038 and precataract surgery VA-adjusted odds ratio = 7.26, 95% CI = 1.06, 49.66, Z = 2.02, P = 0.043). Cox regressions (Table 5) indicated that same-day patients had lower hazards for VA decreases for both time-to-VA < 20/40 (models 4A and 4B) (age-adjusted hazard ratio = 0.34, 95% CI = 0.01, 1.19, Z = −1.69, P = 0.092, marginally significant, and precataract surgery VA-adjusted hazard ratio = 0.17, 95% CI = 0.03, 0.87, Z = −2.13, P = 0.033, significant) and timeto-VA ≤ 20/200 (models 5A and 5B) (age-adjusted hazard ratio = 0.16, 95% CI = 0.02, 1.67, Z = −1.53, P = 0.126 and precataract surgery VA-adjusted hazard ratio = 0.07, 95% CI = 0.00, 1.06, Z = −1.92, P = 0.055, both marginally significant). Figure 2 compares precataract surgery VA-adjusted survival functions by treatment group.
Table 5

Exact Cox proportional-hazards models comparing visual acuity survival times and two-sample tests comparing differential glaucoma progression

Cox proportional hazardsχ2HRZP-value95% CI for HRBootstrapped CI95% BC CI for HRRobust CI95% CI for HRJackknifeΔ signif

Model and eventVariable
4A: Visual acuity < Snellen 20/40Model6.460.040*# BSR = 1000D (1, 9, 12)
Groupa0.34−1.690.092(0.01, 1.19)(0.05, 1.70)(0.11, 1.07)SD (9, 11, 16, 19)
Age1.122.120.034*(1.01, 1.25)(1.03, 1.32)(1.04, 1.20)**
4B: Visual acuity < Snellen 20/40Model14.360.001***# BSR = 1000
Groupa0.17−2.130.033*(0.03, 0.87)(0.01, 1.56)(0.05, 0.95)*None
VApreCS9.173.440.001***(2.59, 32.45)(2.87, 40.92)(3.60, 17.19)***
5A: Visual acuity ≤ Snellen 20/200Model4.890.087# BSR = 1001
Groupa0.16−1.530.126(0.02, 1.67)NMCP(0.02, 1.61)None
Age1.121.540.125(0.97, 1.29)(1.02, 6751.6)(1.04, 1.21)**
5B: Visual acuity ≤ Snellen 20/200Model13.540.001**# BSR = 1027
Groupa0.07−1.920.055(0.00, 1.06)NMCP(0.02, 0.29)***None
VApreCS42.902.450.014*(2.12, 869.3)NMCP(4.24, 433.8)***
Independent-samples t-testmean difftP-value95% CI for mean diffBootstrapped CI for mean diffRobust CI for mean diffJackknifeDelta; signif

6: Differential mean deviation glaucoma progression−5.79−2.880.016*(−10.27, −1.32)(−9.16, −2.43)***(−9.96, −1.63)**D (9)
Mann–Whitney rank-sum testmean diffZP-valuefor the Z statistic

7: Differential pattern-specific deviation glaucoma progression1.662.550.011**N/A(2.08, 3.01)***N/ANone

Notes:

P ≤ 0.05;

P ≤ 0.01;

P ≤ 0.001;

P ≤0.15.

For the group variable, the reference category is delayed vitrectomy.

Abbreviations: age, age at final visit; BC, bias-corrected; BSR, bootstrap repetitions; CI, confidence interval; D ( ), delayed vitrectomy patients; Diff, difference; HR, hazard ratio (HR less than 1 indicates lower risk of a decrease in visual acuity for patients with same-day vitrectomy); N/A, not applicable to this statistical test; NMCP, no meaningful calculation possible, possibly due to the low number of events in the sample; SD ( ), same-day vitrectomy patients; t, t statistic; VApreCS, logMAR visual acuity in the operated eye before cataract surgery; Z, Z statistic; χ2, chi-square statistic; Δ signif, removal of these patients’ data caused a change in the model’s significance.

Figure 2

Comparison of Cox proportional-hazards survival functions for good visual acuity (VA ≥ 20/40) and not bad visual acuity (VA > 20/200), in the operated eye, by treatment group, adjusted for precataract surgery VA in the operated eye.

Data for differential glaucoma progression were available for only four delayed and eight same-day patients. Both the mean MD differential (difference = −5.79, 95% CI = −10.27, −1.32, t = −2.88, P = 0.016) and the mean PSD differential (difference = 1.66, Z = 2.55, P = 0.011) were significant (Table 5, models 6 and 7) and indicated greater glaucoma-related loss of sensitivity in delayed vitrectomy eyes. Table 3 shows estimated mean final MD and PSD for the operated eye, based on precataract surgery values and actual changes in the fellow eye (data not shown) if the patients had been in the other group.

Discussion

The reported incidence of RLF following cataract surgery varied between 0.1% and 1.6%,2,7,23,24 sometimes higher for inexperienced surgeons.3,6,25 Our rate of 0.46% (35/7565) represents the 11-year history at MCF, a single academic institution, with all cataract surgeries performed by five experienced, fellowship-trained cataract surgeons. During this time, MCF developed its no-move, no-wait (more than 15 minutes) policy for same-day vitrectomies. If a cataract surgeon experiences an intraoperative complication with posteriorly dislocated lens fragments, he immediately calls the on-site vitreoretinal surgeon for assistance. The immediate surgical goals include complete pars plana removal of the lens fragments with placement of an IOL. All RLF cases during the past 6 years were handled in this manner. Although some eyes with crystalline RLF are treated medically (at other facilities) with good long-term outcomes, most develop sufficiently severe postoperative complications (elevated IOP, visual obscuration, and inflammation) to warrant removal by vitrectomy. This may be performed during the same surgical episode (depending on the availability, experience, and philosophy of the vitreoretinal surgeon) or delayed. Patient displeasure is common following complicated cataract surgery,1,4 and tends not to improve if reduced VA persists.26 One author reported that “… most [RLF] patients, who had expected a rapid visual recovery after cataract surgery, were very dissatisfied with poor vision post-operatively.”4 Same-day vitrectomy, when feasible, could mitigate patient dissatisfaction,27 prevent the need for a second procedure, and hasten visual recovery.28 Some previous studies have suggested that same-day vitrectomy yields better outcomes5,7,8,29 whereas others have reported poorer same-day outcomes.3,11,23,25 For good VA (≥20/40), three studies favored same-day vitrectomy by >30%: Chen et al8 (36.2%), Romero-Aroca et al7 (35.7%), and Stefaniotou et al5 (31.9%); while three others favored delayed vitrectomy by >10%: Stilma et al23 (26.3%), Borne et al25 (18.75), and Tajunisah and Reddy3 (12.5%). For bad VA (≤/<20/200), two studies favored same-day vitrectomy by >20%: Stefaniotou et al5 (27.8%) and Chen et al8 (22.0%); while two others favored delayed vitrectomy by ≥20%: Tajunisah and Reddy3 (42.9%) and Watts et al11 (20.0%). Compared to our delayed group, our same-day group included more patients with good final VA (78.3% [18/23] versus 58.3% [7/12], difference = 20.7%); fewer patients with bad final VA (4.3% [1/23] versus 25.0% [3/12], difference = 20.7%); and better mean (unadjusted) final VA (20/40 versus 20/90), despite having poorer mean initial VA (20/98 versus 20/75), and older mean age (3+ years). None of these previous studies randomized patients to same-day or delayed vitrectomy, so perhaps these inconsistent same-day versus delayed results have been confounded by different practice patterns and noncomparable treatment groups. Some inconsistency might be due to the fact that many previous studies included same-day vitrectomy patients who were transported between facilities and had much longer (>15 minutes) wait between cataract surgery and vitrectomy. No stratification (by waiting time or location of cataract surgery) was found in any previous analysis of same-day versus delayed vitrectomy outcomes. If waiting time and/or patient movement between surgeries are important factors in the relative success of same-day vitrectomy, then policy differences among facilities could explain why, in some (but not all) studies, same-day vitrectomy produced better outcomes. Perhaps immediate vitrectomy (within 15 minutes) prevents time-dependent inflammation and the accompanying choroidal congestion that occurs with same-day patient transfer between different surgical facilities. Immediate vitrectomy for RLF closely resembles a planned pars plana lensectomy, something frequently performed without complications by vitreoretinal surgeons. Compared to waiting several hours between surgeries, immediate vitrectomy may take advantage of a clear cornea and minimally inflamed eye to enable better removal of RLF with fewer complications. RLF have been linked to new cases of glaucoma,28,30 and although we did not observe a significant difference in new glaucoma cases, we discovered that vitrectomy timing may affect the progression of preexisting glaucoma. Our same-day eyes with preexisting glaucoma experienced less differential visual field loss (glaucoma progression, measured by both MD and PSD, using fellow eyes as controls). Although possible reasons that same-day vitrectomy might have a stabilizing effect on glaucoma are not known, perhaps same-day vitrectomy prevents time-dependent damage to the trabecular meshwork.30 Eyes with RLF begin to develop macrophage-mediated inflammation after 3 days,29,31 and these large cells may exacerbate preexisting glaucoma by further affecting the already-compromised aqueous outflow.29 No other analyses of the effect of vitrectomy timing on the progression of preexisting glaucoma were found in the literature, nor were other analyses found of visual utility and RLF removal timing.

Study limitations

The primary study limitation was the small, nonrandomized sample. A description of our attempts to minimize its effect may be found in the appendix. Our patients were not randomized to vitrectomy timing, because our preferred practice pattern evolved from mostly delayed vitrectomies in the early study period to exclusively same-day vitrectomies in the latter study years. However, there were no significant between-group differences in any precataract surgery variables. We used several statistical techniques, including robust CIs, bootstrapping, and jackknifing to increase confidence in our small sample’s results. In general, robust CIs and bootstrapping validated the primary models’ results (Tables 4 and 5).

Future research

Future researchers, who may have more data, can attempt to verify these findings. We suggest future analyses comparing outcomes for same-day versus delayed vitrectomy stratified by cataract surgery location and adjusting for potential confounding variables (eg, age and precataract surgery VA). Statistical adjustment can mitigate the selection bias inherent in nonrandomized studies, and stratification should yield more homogeneous treatment groups and help determine if vitrectomy delay and/or patient transport between facilities had an effect on the relative success of same-day vitrectomy. Outcomes should be compared for same-day and delayed patients, all of whom had cataract surgery at the same facility as the vitrectomy, possibly with subanalyses limiting the same-day group to only those patients who were not moved to another operating room and who did not wait more than 15 minutes (or another specified time) between cataract surgery and vitrectomy. Separately, outcomes should be compared for same-day and delayed patients, none of whom had cataract surgery at the same facility as the vitrectomy.

Conclusion

These results suggest that same-day vitrectomy for RLF at MCF (performed based on our no-move, no-wait policy) is associated with superior long-term outcomes. Readers should not generalize these results to RLF patients whose same-day vitrectomy was done under different policies for patient waiting and transport. Furthermore, eyes with preexisting glaucoma may benefit from same-day vitrectomy, a result not previously found in the literature. Though our practice’s ability to immediately summon a vitreoretinal surgeon to the operating room is not unique, this is not reproducible for many cataract surgeons. Because the previously published data on same-day vitrectomy are mixed, surgeons should carefully examine their own results to determine if this strategy is appropriate for their practices.
  26 in total

1.  Retained intravitreal lens fragments after phacoemulsification: a clinicopathological correlation.

Authors:  L M Yeo; D G Charteris; C Bunce; P J Luthert; Z J Gregor
Journal:  Br J Ophthalmol       Date:  1999-10       Impact factor: 4.638

2.  Results of vitrectomy performed at the time of phacoemulsification complicated by intravitreal lens fragments.

Authors:  T Kageyama; M Ayaki; M Ogasawara; C Asahiro; S Yaguchi
Journal:  Br J Ophthalmol       Date:  2001-09       Impact factor: 4.638

3.  Pars plana vitrectomy in the management of retained intravitreal lens fragments after cataract surgery.

Authors:  Alvin K H Kwok; Kenneth K W Li; Timothy Y Y Lai; Dennis S C Lam
Journal:  Clin Exp Ophthalmol       Date:  2002-12       Impact factor: 4.207

4.  Clinical features and outcomes of pars plana vitrectomy in patients with retained lens fragments.

Authors:  Ingrid U Scott; Harry W Flynn; William E Smiddy; Timothy G Murray; Jeffrey K Moore; Dagmar R Lemus; William J Feuer
Journal:  Ophthalmology       Date:  2003-08       Impact factor: 12.079

5.  Vitrectomy for retained lens fragments after phacoemulsification.

Authors:  R R Margherio; A R Margherio; S D Pendergast; G A Williams; B R Garretson; L E Strong; M T Trese; M S Cox; T S Hassan
Journal:  Ophthalmology       Date:  1997-09       Impact factor: 12.079

6.  Management of surgically dislocated intravitreal lens fragments by pars plana vitrectomy.

Authors:  W L Hutton; W B Snyder; A Vaiser
Journal:  Ophthalmology       Date:  1978-02       Impact factor: 12.079

7.  Tackling the "dropped nucleus".

Authors:  S Stenkula; E Byhr; S Crafoord; J O Carlsson; M Jemt; G Shanks; U Stenevi
Journal:  Acta Ophthalmol Scand       Date:  1998-04

8.  Retained lens fragments after phacoemulsification.

Authors:  J E Kim; H W Flynn; W E Smiddy; T G Murray; P E Rubsamen; J L Davis; D H Nicholson
Journal:  Ophthalmology       Date:  1994-11       Impact factor: 12.079

9.  Management of nucleus loss into the vitreous: long term follow up in 63 patients.

Authors:  Pedro Romero-Aroca; Juan Fernández-Ballart; Isabel Méndez-Marín; Merce Salvat-Serra; Marc Baget-Bernaldiz; Jose A Buil-Calvo
Journal:  Clin Ophthalmol       Date:  2007-12

10.  Timing of dislocated nuclear fragment management after cataract surgery.

Authors:  Maria Stefaniotou; Miltiadis Aspiotis; Chrisavgi Pappa; Vasilios Eftaxias; Konstantinos Psilas
Journal:  J Cataract Refract Surg       Date:  2003-10       Impact factor: 3.351

View more
  4 in total

Review 1.  Timing of vitrectomy for retained lens fragments after cataract surgery.

Authors:  Travis Peck; Janice Park; Asima Bajwa; Yevgeniy Shildkrot
Journal:  Int Ophthalmol       Date:  2017-09-27       Impact factor: 2.031

2.  Retinal detachment after vitrectomy performed for dropped nucleus following cataract surgery: a retrospective case series.

Authors:  Hacı Koç; İbrahim Koçak; Salih Bozkurt
Journal:  Int J Clin Exp Med       Date:  2015-03-15

3.  Meta-analysis comparing same-day versus delayed vitrectomy clinical outcomes for intravitreal retained lens fragments after age-related cataract surgery.

Authors:  Elizabeth A Vanner; Michael W Stewart
Journal:  Clin Ophthalmol       Date:  2014-11-18

4.  Visual and Anatomical Outcomes of Pars Plana Vitrectomy for Dropped Nucleus after Phacoemulsification.

Authors:  Ali Lashgari; Majid Kabiri; Alireza Ramezani; Morteza Entezari; Saeed Karimi; Sajad Kakaei; Mehdi Yaseri; Homayoun Nikkhah
Journal:  J Ophthalmic Vis Res       Date:  2018 Jul-Sep
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.